Boston-based biotechnology company Life Biosciences announced that it has collected $50 million in Series B financing.
The company initially targeted a $25 million in funding but upsized to reach investor demand.
Life Biosciences will use the net results for research and development activities in potential therapeutics to combat age-related decline, and related purposes.
The round was joined by a range of investors including individuals, family trusts, and other professional investors.